An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Vista sencilla de ítem
dc.creatorGeurtsvanKessel, Corine H.
dc.creatorOkba, Nisreen M. A.
dc.creatorIgloi, Zsofia
dc.creatorBogers, Susanne
dc.creatorEmbregts, Carmen W. E.
dc.creatorLaksono, Brigitta M.
dc.creatorLeijten, Lonneke
dc.creatorRokx, Casper
dc.creatorRijnders, Bart
dc.creatorRahamat-Langendoen, Janette
dc.creatorvan den Akker, Johannes P. C.
dc.creatorvan Kampen, Jeroen J. A.
dc.creatorvan der Eijk, Annemiek A.
dc.creatorvan Binnendijk, Rob S.
dc.creatorHaagmans, Bart
dc.creatorKoopmans, Marion
dc.date.accessioned2020-07-22T20:33:11Z
dc.date.available2020-07-22T20:33:11Z
dc.date.created2020-07-06
dc.description.abstractenglishThe world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications.spa
dc.format.extent5 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41467-020-17317-yspa
dc.identifier.issn2041-1723spa
dc.identifier.otherhttps://www.nature.com/articles/s41467-020-17317-yspa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10982
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleAn evaluation of COVID-19 serological assays informs future diagnostics and exposure assessmentspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41467-020-17317-y.pdf
Tamaño:
595.92 KB
Formato:
Adobe Portable Document Format
Descripción:
Ver documento
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS